



Fig 5 Contribution of abdominal obesity (increased waist measurement) as therapeutic target for better management of risk of coronary heart disease

chart of every patient. Obviously, as our sedentary life-style combined with our diet rich in saturated fats and *trans* fatty acids and in refined sugars is “toxic” to our metabolism, any approach aimed at the management of risk of coronary heart disease in abdominally obese patients will require a multifaceted approach (balanced nutrition with more vegetables and fruit, fewer refined products rich in fat and sugar, more physical activity) directed at the critical factors involved in the aetiology of the patient’s condition. In a broader context of a comprehensive evaluation and treatment of risk (and not of body weight), it is hoped that this approach will help physicians to identify obese patients that may require pharmacotherapy aimed at waist rather than weight management.

Competing interests: J-PD has received honoraria for consultancy and lectures and funding for his laboratory from Servier Canada, Parke-Davis/Warner-Lambert Canada, Merck-Frosst Canada, Fournier Pharma, Gatorade, DuPont-Merck, Knoll Pharma, Weight Watchers International, Roche Pharma, and Eli Lilly.

Funding: This work was supported by the Canadian Institutes of Health Research (MT-14014 and MGC-15187). J-PD is chair professor of human nutrition and lipidology, which is supported by Parke-Davis/Warner-Lambert, Proviso, and the Foundation of the Quebec Heart Institute. IL is recipient of a fellowship from the Heart and Stroke Foundation of Canada.

- 1 Bray GA, Bouchard C, James WPT, eds. *Handbook of obesity*. New York: Marcel Dekker, 1998.
- 2 National Heart, Lung, and Blood Institute/National Institutes of Diabetes and Digestive and Kidney Diseases. *Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The evidence report*. Bethesda: National Institutes of Health, 1998:1-228.
- 3 WHO Consultation on Obesity. *Preventing and managing the global epidemic*. Geneva: World Health Organization, 1997:1-276.
- 4 Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. *J Chronic Dis* 1972;25:329-43.
- 5 Vague P. La différenciation sexuelle, facteur déterminant des formes de l'obésité. *Presse Med* 1947;30:339-40.
- 6 Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. *Med Clin North Am* 1989;73:111-38.
- 7 Terry RB, Stefanick ML, Haskell WL, Wood PD. Contributions of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women: possible protective effects of thigh fat. *Metabolism* 1991;40:733-40.
- 8 Poulriot MC, Després JP, Nadeau A, Tremblay A, Moorjani S, Lupien PJ, et al. Associations between regional body fat distribution, fasting plasma free fatty acid levels and glucose tolerance in premenopausal women. *Int J Obes* 1990;14:293-302.
- 9 Poulriot MC, Després JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 1994;73:460-8.
- 10 Lemieux S, Prud'homme D, Tremblay A, Bouchard C, Després JP. Anthropometric correlates to changes in visceral adipose tissue over 7 years in women. *Int J Obes Relat Metab Disord* 1996;20:618-24.
- 11 Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. *Diabetes Metab Rev* 1987;3:463-524.

- 12 Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. *Diabetes* 1990;39:104-11.
- 13 Poulriot MC, Després JP, Nadeau A, Moorjani S, Prud'homme D, Lupien PJ, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. *Diabetes* 1992;41:826-34.
- 14 Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Arteriosclerosis* 1990;10:497-511.
- 15 Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapoprotein B, small, dense LDL) in men? *Circulation* 2000;102:179-84.
- 16 Castelli WP. Epidemiology of coronary heart disease: the Framingham study. *Am J Med* 1984;76:4-12.
- 17 Tchernof A, Lamarche B, Prud'homme D, Nadeau A, Moorjani S, Labrie F, et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. *Diabetes Care* 1996;19:629-37.
- 18 Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. *JAMA* 1998;279:1955-61.
- 19 Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Després JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. *Am J Clin Nutr* 1996;64:685-93.
- 20 Lemieux S, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Després JP. Seven-year changes in body fat and visceral adipose tissue in women. Association with indexes of plasma glucose-insulin homeostasis. *Diabetes Care* 1996;19:983-91.
- 21 McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. *Arterioscler Thromb* 1992;12:1284-90.
- 22 Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. *BMJ* 1995;311:158-61.
- 23 Lean ME, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. *Lancet* 1998;351:853-6.
- 24 Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. *BMJ* 1995;311:1401-5.
- 25 Williamson DF. Pharmacotherapy for obesity. *JAMA* 1999;281:278-80.
- 26 Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European multicentre orlistat study group. *Lancet* 1998;352:167-72.

(Accepted 21 December 2000)

Corrections and clarifications

How animal passions became aroused

Two errors occurred in this review of the television documentary *The Rise and Rise of Animal Rights* by Rhona MacDonald (27 January, p 244). Firstly, we should of course have spelt Colin Blakemore's name correctly. Secondly, the article wrongly stated that the Royal Society for the Prevention of Cruelty to Animals (RSPCA) was formed in the 1960s. The society was in fact formed in 1824 (as the Society for the Prevention of Cruelty to Animals) and with royal approval became the RSPCA in 1840.

Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis

In this fast track paper by James A Kaye and colleagues (24 February, pp 460-3), perhaps the editing was just too fast. We failed to pick up that the title of the table should have referred to median [not mean] age.

Recent advances: Urology

Some confusion has arisen over a slightly inaccurate reference in this article by Paul Abrams and Alan Wein (2 December, pp 1393-6). The article in reference 20 was published in a supplement to *European Urology*, called *Curriculum in Urology 1.3*, and not in the main journal, as was stated. The correct reference is: De Jong TPVM. Treatment of bladder exstrophy and epispadias. *Eur Urol* 1999;36(suppl):1-7.